(INDIANAPOLIS, IN) - The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly and Company's Cymbalta for the maintenance treatment of generalized anxiety disorder in adults.
It marks the sixth approved use for the drug.
Cymbalta is also used to treat major depressive disorder, the management of diabetic peripheral neuropathic pain and fibromyalgia.
Company officials say generalized anxiety disorder affects nearly seven million Americans at any given time.
Have a question or comment about a news story? Send it to email@example.com